- MediPharm Labs ( OTCQX:MEDIF ) ( TSX: LABS:CA ) will acquire VIVO Cannabis ( OTCQB:VVCIF ) ( TSX: VIVO:CA ) in an all-equity business combination transaction.
- The two companies have entered into a definitive arrangement agreement for the acquisition, as part of which existing MediPharm shareholders are expected to own between 65% and 79% of the combined company and VIVO shareholders between 35% and 21%.
- VIVO shareholders will receive between 0.2110 and 0.4267 shares of MediPharm for each VIVO share held.
- The acquisition will add Australian and German medical cannabis brand Beacon Medical to the combined company.
- VIVO's medical sales channel, Canna Farms Medical, is anticipated to provide patients with a more diverse product portfolio.
- The combined company would have annualized international revenue of over $20M, based on Q3 2022.
- The anticipated combined cash position would be of ~$30M.
- Source: Press Release
For further details see:
MediPharm Labs to acquire VIVO Cannabis in all-equity transaction